Nasdaq

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...
Nasdaq

Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Seeking Alpha

Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025

SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
Morningstar

Epredia’s E1000 Dx Digital Pathology Solution Wins 2025 International Scanner Benchmark Awards from the Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA)

The Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA), an international organization that advances the use of validated AI solutions in clinical practice, has announced that Epredia, a ...
Morningstar

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ ...